Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028 Multiple Sclerosis Drug Candidate Lucid-21-302 Phase 1 Trial with Toxicology Studies Complete, and unbuzzd™ Clinical Trial Published in Peer-Reviewed Journal TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Quantum’s strong balance sheet and overall progress continue, and management is confident that there is sufficient working capital, as of the date of filing these Financial Statements, to carry out its operations over the next...

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), a leading developer of the world’s largest resource of critical metals essential to energy, defense, manufacturing and infrastructure, today provided a corporate update and fourth quarter and full year financial results for the period ending December 31, 2025. Fourth Quarter and Full Year 2025 Financial HighlightsTotal cash of approximately $117.6 million at December 31, 2025 $11.4 million cash used in operations for the quarter ended December 31, 2025 Operating loss of $44.7 million, net loss of $40.4 million and net loss per share of $0.08 for the quarter ended December 31, 2025Exclusive Negotiations Underway for Nodule Processing & Refining Hub in Brownsville, TexasExclusive negotiations for 1,466 acres with...

SHOEMAKERSVILLE, Pa., March 27, 2026 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced financial results for its fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter vs. Prior Year Period:Net sales decreased to $25.1 million compared to $37.3 million. Gross Profit Margin increased to 8.5% of net sales compared to 4.9%. Adjusted Gross Profit Margin(1) increased to 15.4% of net sales compared to 9.6%. SG&A expense and Adjusted SG&A(1) expense decreased by 43.5% and 18.9%, respectively. Net loss increased to $242.2 million compared to $17.5 million. Net loss in the fourth quarter of 2025 included a non-cash...

Revenue growth driven by expanding Builder+ block-building activity, with Imperium delivering $1.3 million in revenue following its Q3’25 launch WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, a company focused on blockchain infrastructure and decentralized finance operations, today announced its financial results for the year ended December 31, 2025 (“FY 2025”). The Company also released an updated investor presentation available at www.btcs.com/investors/. “2025 was a transformative year for BTCS as we scaled our Ethereum-first operating model and delivered record revenue,” said Charles Allen, Chief Executive Officer of BTCS. “Revenue grew over 300%, driven by the expansion of Builder+, our block-building business, and the successful...

~ Q4 2025 Delivers Strongest Revenue Quarter of the Year ~ ~ Debt-Free Balance Sheet and $14M in Year-End Cash Enable Focus on Execution ~ ~ Diversified Revenue and Shift to Scalable Offerings Support Path to Profitable Future ~ SANTA MONICA, March 27, 2026 (GLOBE NEWSWIRE) —  Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company that generates revenue by executing interactive advertising and immersive content programs for brands seeking to reach and influence people who play video games, today released fourth quarter and full year 2025 financial results. Super League Chief Executive Officer, Matt Edelman Commented: “Super League is a fundamentally different company than it was a year ago. We have a stronger foundation and a clearer path to scale, positioned to help brands reach and influence...

– Fourth quarter revenue of $2.4 million, up 8.7% sequentially and 19.2% year-over-year TAMPA, Fla., March 27, 2026 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today reported financial results for the three and twelve months ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal revenue for the fourth quarter ended December 31, 2025 was $2.4 million dollars, up 8.7% sequentially from Q3 2025 and 19.2% for the quarter year-over-year. The sequential increase reflects higher Bitcoin production but partial offset by a lower average Bitcoin price. The Company mined 22.0 Bitcoin during the fourth quarter 2025 at an average price of approximately $99,700, compared to 17.6 Bitcoin in Q3 2025 at an average Bitcoin value of approximately...

– Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year –  – Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia – – Submitted of a Marketing Authorization Application with the Israel Ministry of Health – – U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels – – Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access – – Conference call today at 8:00 am ET – DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered...

sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch plans based on third-party market assessment NEW HAVEN, Conn., March 27, 2026 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today reported financial results for the fourth quarter and full-year 2025 and provided an update on its late-stage pipeline and commercial launch readiness plans. The Company submitted a supplemental New Drug Application (sNDA) in January to the U.S. Food and Drug Administration (FDA) seeking label...

Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 27, 2026 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth quarter and full year 2025 financial results and provided a corporate update. Recent Highlights:In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. to terminate the license and collaboration agreement for AXN-2510 and AXN-27M. Following this decision, Instil...

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy (“Duchenne” or “DMD”)Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 monthsReported proteomic data from CL-101 (28-day Phase 1b trial in adults with DMD) at MDA, showing reductions in established biomarkers of muscle degeneration...